One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-146681
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 1 |
Affiliation: The University of Texas MD Anderson Cancer Center, Roswell Park Cancer Institute, European Institute of Oncology, Dana-Farber Cancer Institute, Harvard University, Duke University, Moffitt Cancer Center, ImmunoGen (United States), City of Hope, Centre Hospitalier Universitaire Amiens-Picardie, Istituto Oncologico Romagnolo, Hospital Universitari i Politècnic La Fe, Fred Hutch Cancer Center, Texas Oncology, Duke Medical Center, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Centre Hospitalier Universitaire de BesançonA Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
